Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.
Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes.
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
Novo Nordisk and University of Oxford have expanded their partnership on researching type 2 diabetes, and will open a new research centre in Oxford.
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
Novo Nordisk has initiated a share repurchase programme in accordance with certain European regulations known as the Safe Harbour rules.
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014…
France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.